Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study — A Single-Center, Blinded, Randomized Controlled Trial

Robin Chung, MPhil, MBBS, MRCP; Angshuman Maulik, BSc, MBBS; Ashraf Hamarneh, MBChB, MRCP; Daniel Hochhauser, DPhil, FRCP; Derek J. Hausenloy, PhD, FRCP, FACC; J. Malcolm Walker, MD, FRCP; Derek M. Yellon, PhD, DSc, FRCP, FACC, FESC
The Hatter Cardiovascular Institute (Chung, Maulik, Hamarneh, Hausenloy, Walker, Yellon), University College London, London, United Kingdom; Research Department of Oncology (Hochhauser), The Cancer Institute, University College London, London, United Kingdom; Cardiovascular and Metabolic Disorders Program (Hausenloy), Duke University–National University of Singapore Medical School, Singapore

Cancer survival continues to improve, and thus cardiovascular consequences of chemotherapy are increasingly important determinants of long-term morbidity and mortality. Conventional strategies to protect the heart from chemotherapy have important hemodynamic or myelosuppressive side effects. Remote ischemic conditioning (RIC) using intermittent limb ischemia-reperfusion reduces myocardial injury in the setting of percutaneous coronary intervention. Anthracycline cardiotoxicity and ischemia-reperfusion injury share common biochemical pathways in cardiomyocytes. The potential for RIC as a novel treatment to reduce subclinical myocyte injury in chemotherapy has never been explored and will be investigated in the Effect of Remote Ischaemic Conditioning in Oncology (ERIC-ONC) trial (clinicaltrials.gov NCT 02471885). The ERIC-ONC trial is a single-center, blinded, randomized, sham-controlled study. We aim to recruit 128 adult oncology patients undergoing anthracycline-based chemotherapy treatment, randomized in a 1:1 ratio into 2 groups: (1) sham procedure or (2) RIC, comprising 4, 5-minute cycles of upper arm blood pressure cuff inflations and deflations, immediately before each cycle of chemotherapy. The primary outcome measure, defining cardiac injury, will be high-sensitivity troponin-T over 6 cycles of chemotherapy and 12 months follow-up. Secondary outcome measures will include clinical, electrical, structural, and biochemical endpoints comprising major adverse cardiovascular clinical events, incidence of cardiac arrhythmia over 14 days at cycle 5/6, echocardiographic ventricular function, N-terminal pro-brain natriuretic peptide levels at 3 months follow-up, and changes in mitochondrial DNA, micro-RNA, and proteomics after chemotherapy. The ERIC-ONC trial will determine the efficacy of RIC as a novel, noninvasive, nonpharmacological, low-cost cardioprotectant in cancer patients undergoing anthracycline-based chemotherapy.

Introduction
Cancer affects more than 1 in 3 people in their lifetime and, together with cardiovascular diseases, remains the leading causes of morbidity and mortality in developed nations. Cancer outcomes continue to improve such that long-term 10-year survival for all cancers now stands at 50%, and 80% or better for breast, prostate, Hodgkin’s lymphoma, and melanoma. Cancer survivors will make up more than 5% of the US population by 2022, and nearly 25% of the UK population aged 65 years and older by 2040. These welcome improvements in primary cancer outcomes give
Cardioprotection to limit myocardial damage from anthracycline chemotherapy has to date focused on 2 approaches: modified doxorubicin preparations and pharmacological treatments. Revised infusion strategies using lower dose,23 continuous infusion,24 liposomal doxorubicin,25,26 iron chelation,27–29 and anti–heart failure medications have all demonstrated some success in mitigating myocardial injury. Up to half of myocyte cell death during acute myocardial infarction is caused by reperfusion itself.30 Remote ischemic conditioning (RIC), via repeated cycles of inflation and deflation of a peripheral arm blood pressure cuff, reduces myocardial injury in anthracycline-treated cancer patients.

The Effect of Remote Ischaemic Conditioning in Oncology Patients Study

Hypothesis

Remote ischemic conditioning (RIC), via repeated cycles of inflation and deflation of a peripheral arm blood pressure cuff, reduces myocardial injury in anthracycline-treated cancer patients.

Study Objectives

The Effect of Remote Ischaemic Conditioning in Oncology Patients (ERIC-ONC) study will be a proof-of-concept study to investigate the effect of RIC in oncology patients. The study objective is to determine whether RIC reduces cardiac biomarker evidence of subclinical myocardial cardiotoxicity during anthracycline-based chemotherapy treatment. Primary and secondary outcome measures are detailed in the Study Endpoints section and summarized in Table 1.

Methods

Study Design

The ERIC-ONC study will be a single-center, blinded, randomized, sham-controlled trial. The ERIC-ONC study has been reviewed and approved with a favorable opinion from the United Kingdom National Research Ethics Service (NRES) (London-Chelsea Committee NRES REC reference: 15/LO/1116). The ERIC-ONC study protocol is registered on the public trials database clinicaltrials.gov NCT 02471885 (Figure 2).

Study Population

The ERIC-ONC study will be conducted at a single tertiary cancer referral center in London, United Kingdom. Patient inclusion criteria are summarized in Table 2. Participants will be recruited from adult oncology patients newly referred for anthracycline chemotherapy (Eastern Cooperative Oncology Group performance status ≤3), 18 to 80 years of age, who can provide informed consent (based on Cancer Research United Kingdom data38 documenting one-third of all new cancers were diagnosed in patients 75 years old and older, with the 50- to 74-year-old age group accounting for 43% of all cancer deaths).

Patients will be excluded if they have had a recent myocardial infarction (acute coronary syndrome) in the previous 4 weeks, or have a defined cardiac diagnosis that may raise baseline cardiac biomarkers above the reference 99th centile such as dilated cardiomyopathy, hypertrophic cardiomyopathy,39 cardiac amyloidosis,39,40 or Anderson-Fabry disease41 diagnosed or treated at our tertiary cardiac center. Patients will also be excluded if they have significant peripheral vascular disease defined as upper limb claudication by symptoms or imaging, chronic kidney disease with estimated glomerular filtration rate <30 mL/min/1.73 m², or taking sulfonylureas. Patients unable to tolerate peripheral arm blood pressure cuff inflation due to bilateral lymph node dissection, peripherally inserted central catheter, or significant thrombocytopenia (platelet count <100,000/μL) will be excluded.

Cardioprotection

Cardioprotection is an important aspect of long-term patient care.

Cardiotoxicity of Anthracyclines

Anthracyclines exert their cytotoxic effect via topoisomerase II inhibition and intercalation of DNA.6 However, this effect—but nonselective—antitumor mechanism has cardiotoxic consequences. Anthracycline cardiotoxicity is classically attributed to lipid peroxidation and iron-complex reactive oxidation species (ROS),7–10 to which the myocyte is particularly vulnerable owing to a lack of catalase, glutathione peroxidase, and limited regenerative capacity.11–13 Cardiomyocytes are vulnerable to anthracycline injury because they express topoisomerase II-β,10,14 but additional myocyte damage is caused through calcium dys-regulation and mitochondrial permeability transition pore (MPTP) disruption.15–17

Anthracycline cardiotoxicity, defined initially as clinical heart failure, was reported soon after the anthracyclines’ widespread introduction in the 1960s.18 This led to the current practice of limiting the cumulative doxorubicin dose to a lower cutoff of 400 mg/m². Longitudinal studies documented high mortality from anthracycline-induced congestive heart failure—60% at 2 years18–20—with image-based subclinical cardiac dysfunction occurring in at least 9%21 to 18%.22

Clinical Cardiology 39, 2, 72–82 (2016)
R. Chung et al: The ERIC-ONC study
Published online in Wiley Online Library (wileyonlinelibrary.com)
DOI: 10.1002/clc.22507 © 2016 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
Figure 1. Reperfusion injury and doxorubicin cardiotoxicity pathways. Pathological activation of RoS formation, calcium overload, and altered mitochondrial respiration in reperfusion injury are also found in anthracycline cardiotoxicity. (Reproduced under license from Yellon and Hausenloy(86) and the Massachusetts Medical Society/New England Journal of Medicine.). Abbreviations: ICAM-1, intercellular cell adhesion molecule-1; NADPH, nicotinamide adenine dinucleotide phosphate hydrogen; PTP, permeability transition pore.

Chemotherapy Regimens
Participants recruited to the study will undergo, as part of their standard cancer treatment, typically 6 cycles of anthracycline-based chemotherapy occurring at 1 to 3 weekly intervals in the University College London Hospital-Macmillan Cancer Centre. The participant’s usual cancer chemotherapy care will only be altered along standard clinical guidelines by their usual oncology team.

Intervention
The RIC intervention will be delivered as 4 cycles of upper arm blood pressure cuff inflation to 200 mm Hg (or 20 mm greater than systolic blood pressure) for 5 minutes to induce transient noninjurious limb ischemia, followed by cuff deflation for 5 minutes. Participants randomized to the sham control arm will receive 4 cycles of upper arm blood pressure cuff inflation to 10 mm Hg.
for 5 minutes to simulate treatment, followed by cuff deflation for 5 minutes. Both treatments will last 40 minutes and will be applied before the start of planned chemotherapy. If patients are unable to tolerate all 4 cycles of cuff inflation, they will still be included in the study, as there is evidence that a single cycle of RIC confers cardioprotection.42

**Randomization and Blinding**

On the day of the first chemotherapy infusion, patients will be randomly allocated in a 1:1 ratio to either the RIC or sham group, using the following minimization factors: diabetes, hypertension, and coronary artery disease to ensure that groups are evenly matched in terms of cardiotoxicity risk factors.22,43 Randomization will be performed using MinimPy 0.3 software (http://minimpy.sourceforge.net) on a laptop by an unblinded nurse specialist who will not be involved in data analysis.

**Study Endpoints**

The primary outcome measure for the ERIC-ONC study will be high-sensitivity troponin-T (hsTnT) measured at baseline/prechemotherapy cycle, and at 6 to 24 hours after chemotherapy cycles, then at 1, 3, 6, and 12 months follow-up. Study outcome measures are summarized in Table 1.

Secondary outcome measures will include a composite clinical endpoint for major adverse cardiovascular events (MACCE) at 1, 3, 6, and 12 months follow-up, defined as myocardial infarction, clinical heart failure requiring admission, life-threatening cardiac arrhythmia, atrioventricular block requiring pacemaker, or cardiac or cancer death. Participants will be screened at regular study visits for any MACCE leading to admission at their local hospital or the tertiary center, adjudicated by a cardiologist. These data will be entered onto an individual case report form (CRF) and archived electronically onto the Research Electronic Data Capture (REDCap) system.44 We intend to perform echocardiograms on a uniform GE E9 ultrasound system (GE Healthcare, Waukesha, WI) to measure ventricular chamber dimensions, ejection fraction, and longitudinal strain at baseline, 3 months, and 12 months using the TomTec Arena (TomTec Imaging Systems, Unterschleissheim, Germany) speckle tracking package at our core lab. Cardiac arrhythmia, at chemotherapy cycle
Figure 2. Study flowchart diagram. Abbreviations: BP, blood pressure; DCM, dilated cardiomyopathy; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; FBC, full blood count; HCM, hypertrophic cardiomyopathy; hsTnT, high-sensitivity troponin-T; LN, lymph node; NT pro-BNP, N-terminal pro-brain natriuretic peptide; RIC, remote ischemic conditioning; U+E, urea and electrolytes.
Troponin curve, with control group 1 hsTnT = peak hsTnT values as parameters to characterize the without echocardiographically defined cardiotoxicity (using 2, anticipated standard deviation 7.8 ng/L, and RIC intervention group 2). We therefore hypothesized a predicted treatment effect of reduced troponin release, ranging from 18 to −62%. We therefore hypothesized a predicted treatment effect of −35% with 80% power at the 5% significance level, and we calculated a sample size of 128 participants (n = 64 in each arm of the study). This calculation was based on the only hsTnT cardiotoxicity study to date by Katsurada et al in breast cancer chemotherapy patients with and without echocardiographically defined cardiotoxicity (using peak hsTnT values as parameters to characterize the troponin curve, with control group 1 hsTnT = 11 ng/L, standard deviation 7.8 ng/L, and RIC intervention group 2), anticipated −35% difference to 7.15 ng/L, on 1:1 ratio, with an α = 0.05, power = 80%).

### Statistical Analysis

The effect of RIC treatment on hsTnT levels at baseline, at 6 to 24 hours and prior to each chemotherapy cycles, and at 3, 6, and 12 months, will be recorded a continuous variable. Serial data at time points will be compared using a repeated measures mixed effects model. We will analyze missing data by intention to treat analysis and multiple imputation in consultation with a statistician, depending on whether the data were missing at random or not, respectively. Categorical data will be analyzed using Fisher exact test or $\chi^2$ test if frequency $>5$. We will use Cox proportional hazards regression to calculate hazard ratios, and the Kaplan-Meier function to visualize the cumulative incidence for MACCE. Comparisons will be deemed statistically significant with a $P < 0.05$.

### Data Management, Governance, and Funding

The ERIC-ONC trial is funded under the National Institute of Health Research Biomedical Research Centre and sponsored by University College London. Data will be collected on a CRF and managed using REDCap electronic data capture tools. REDCap is a secure, Web-based application designed to support validated and audited data capture tools. REDCap is a secure, Web-based application designed to support validated and audited data capture for research studies. An independent data monitoring committee will be convened to monitor the progress and safety of the study.

### Discussion

There is no universally accepted definition of cardiotoxicity. Historically, cardiotoxicity has been characterized along clinical grounds (eg, overt heart failure) and more recently by noninvasive imaging based on ejection fraction (ie, either as a symptomatic 5% fall or an asymptomatic 10% fall in ejection fraction to less than normal values). Current consensus guidelines suggest that biomarker rise may be more sensitive in detecting early asymptomatic cardiotoxicity to guide imaging assessment.

In addition to its central role in the universal definition of ACS and prognosis, troponin predicts outcomes in other forms of heart disease, as well as anthracycline-induced cardiotoxicity. The evidence base shows that...
30% to 40% of anthracycline patients demonstrate a troponin-positive trend during treatment, but these historical data fluctuate according to troponin assay. Peak troponin-I/T values, though not directly comparable, range from 11 to 120 ng/L, and 160 to more than 1000 ng/L, in low-dose and high-dose anthracycline regimens, respectively (Table 3). Myocardial injury and subsequent troponin release rises progressively with cumulative anthracycline dose.64 There is a single manufacturer of the hsTnT assay (Elecsys; F. Hoffmann-La Roche, Basel, Switzerland). The current generation Roche hsTnT assay for the ERIC-ONC study can be directly compared across all centers utilizing the sole hsTnT assay, enabling generalization of results and facilitating comparison in future studies. This quantitative 1-step troponin-T enzyme immunoassay is specified with a 10% coefficient of variation upper limit of normal set at 14 ng/L, limit of detection = 5 ng/L, measurement range 3 to 10,000 ng/L.

The most widely used imaging measurement of cardiotoxicity is ejection fraction, either by echocardiogram or multigated acquisition scan, but this measurement has important limitations in terms of precision and...
repeatability.62 Furthermore, morphological studies have shown no linear association between biopsy findings and ejection fraction.63 More recent work has demonstrated biomarker evidence of myocardial injury even after the first cycle of anthracycline therapy60,64 before a fall in ejection fraction, implying there may be no safe threshold below which detectable myocardial injury does not occur. Participants will undergo clinical and research echocardiograms according to clinical and study protocols. Imaging evidence of subclinical cardiotoxicity, defined as an asymptomatic fall in left ventricular ejection fraction of >10%, will be discussed with oncology for initiation of angiotensin-converting enzyme inhibitor and/or β-blocker therapy.65

Cardiac arrhythmia is common (in excess of 12%) in cancer patients and affects morbidity and mortality.66,67 but prospective studies have been relatively small and monitored for short durations.58,69 We will monitor prospectively in all 128 participants the incidence of cardiac arrhythmia. Participants will wear an electrocardiogram patch after penultimate cycle 5 of chemotherapy treatment for 14 days to span the period when we expect RIC to confer antiarrhythmic protection43,69,70 from the cumulative effect of anthracyclines,60,61,70 consistent with a putative role for mitochondrial dysfunction in arrhythmogenesis.71

Pharmacological treatments to reduce myocyte damage during chemotherapy include antioxidants, iron chelation, and standard heart failure medications. Antioxidant strategies have proved disappointing72,73; therapies such as L-carnitine, co-enzyme Q10, N-acetylcysteine, and phenethyldiamines have proved disappointing in children and equivocal in adults,74 possibly because antioxidants exert their effect after free radical formation. Renin-angiotensin-system inhibition,75 statin therapy,76 and β-blockers77,78 have shown promise in adult cardioprotection,79,80 but their universal adoption is constrained by interactions with renal function, transaminitis/myositis, and hemodynamic side effects, respectively. Dexrazoxane is 1 of only 2 iron chelators (along with deferiprone)27 that demonstrated cardioprotective effects28,29 by limiting cardiac troponin rise in pediatric and adult hematological patients. However, dexrazoxane may cause myelosuppression, and its regulatory license26 is limited to cancer patients embarking on extended courses of anthracycline chemotherapy, rather than initial chemotherapy treatment. Furthermore, the incidence of secondary malignancy following dexrazoxane remains highly controversial.81–83 Thus, to date, pharmacological interventions have demonstrated variable success and their wider use limited by licensing constraints or side effect profiles.

The phenomenon of ischemic conditioning as a form of cardioprotection against ischemia was described by Murry et al in 1986 as activation of endogenous cardioprotective mechanisms to limit myocardial infarct size through repeated cycles of nonlethal ischemia-reperfusion before an index episode of prolonged ischemic injury.30 Ischemic conditioning exerts its cardioprotective effects via ligands such as adenosine, bradykinin, and opioid cell surface receptors acting on downstream signaling cascades involving recruitment of what has been termed the reperfusion injury salvage kinase pathway. This in turn is thought to cause inhibition of MPTP opening and inhibition of reactive oxidation species ROS.84 Yellon’s group demonstrated that mechanical RIC with a blood pressure cuff85,86 could also confer cardioprotection via a noninvasive, nonpharmacological technique.45,46

As a nonpharmacological treatment in the setting of elective coronary artery bypass graft surgery, RIC reduced myocardial injury by decreasing troponin rise by 18% to 43%.45,46,48 RIC also decreased troponin rise after primary percutaneous coronary intervention (PCI) by 50% to 63%.47,87,88 Improved myocardial salvage by 26%,89 and reduced myocardial infarction size by 27%.90 RIC was associated with decreased frequency of atrial fibrillation by more than 50% in coronary artery bypass grafting (CABG)45 and abolished it in a small series of aortic valve replacement patients.91 RIC decreased the incidence and extent of acute kidney injury by 30% in the setting of elective high-risk cardiac surgery.92 It improved medium-term clinical outcomes by reducing (MACCE after CABG at 1.5 years.48 and in primary PCI by more than 40% at a median follow-up of 3.8 to 4.3 years.87,93 RIC appears to exert a neutral effect on outcomes in CABG surgery (the ERICCA study [Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery]; clinicaltrials.gov identifier NCT01247545).94,95 poten
dially due to the use of intraoperative protocol95. Long-term outcomes in PCI are being investigated (ERIC-PCI study [Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PCI]); clinicaltrials.gov NCT02342522). Cuff inflation is well-tolerated with few side effects. Martin-Gill et al96 reported the tolerability of RIC with 83% of 99 air ambulance transport patients tolerating 5 or 4 cycles of RIC over 25 to 35 minutes, with 53% reporting no pain and only 5% reporting moderate 5 out of 10 discomfort. Similarly, Li et al97 reported no adverse effects in 216 patients.

To date, there are few studies applying RIC to organ protection in cancer treatment and no comparable studies investigating RIC cardioprotection in the setting of cancer chemotherapy. Li et al179 demonstrated the effectiveness of RIC in attenuating acute lung injury in cancer patients, reducing oxygenation requirements and postoperative stay in lung resection surgery. Thus, RIC confers cardioprotection, renal protection, and lung protection against ischemic injury.

The ERIC-ONC trial will be the first study to investigate the efficacy of remote ischemic conditioning as a novel form of noninvasive, nonpharmacological cardioprotection against anthracycline chemotherapy. We anticipate our study will establish the effectiveness of RIC to precondition and protect the heart against subclinical biochemical, structural, electrical, and metabolic cardiac injury in the cardio-oncology setting as a pilot for a future multicenter trial.

Acknowledgments
The authors are grateful to Dr. Roger Rear for his insight into the design of an RIC trial, and Dr. Laura Cove-Smith for her suggestions regarding biomarker cardiotoxicity.
References

1. Cancer Research UK. Survive cancer for 10 or more years, 2010–11. England and Wales. http://www.cancerresearchuk.org/health-professional/cancer-statistics/survival. Accessed April 2014.

2. Siegel R, Desantis C, Virgo K. Cancer treatment and survivorship statistics. Cancer J Clin. 2012;62:220–241.

3. Maddams J, Utey M, Moller H. Projections of cancer prevalence in the United Kingdom, 2010–2040. Br J Cancer. 2012;107:1195–1202.

4. Kero AE, Järveli LS, Arola M, et al. Cardiac effects of doxorubicin in long-term survivors of early-onset cancer: a population-based study. Int J Cancer. 2014;134:664–673.

5. Ding Y, Shen Q, Herrick K. Cause of death in cancer survivors [abstract]. Cancer Res. 2012;72:LB-339.

6. Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466–468.

7. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983;43:460–472.

8. Link G, Tirosch R, Finnson A. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med. 1989;122:272–278.

9. Lyu YL, Kerrigan JE, Lin C, et al. Topoisomerase II-beta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity prevention by dexrazoxane. Cancer Res. 2007;67:8839–8846.

10. Zhang S, Lu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Med. 2012;18:1369–1363.

11. Ali SR, Hippenmeyer S, Saadat LV, et al. Existing cardiomyocytes generate cardiomyocytes at a low rate after birth in mice. Proc Natl Acad Sci U S A. 2014;111:8850–8855.

12. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010;7:546–555.

13. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428:664–668.

14. Veijongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2014;64:938–945.

15. Dodd DA. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest. 1993;91:1687–1705.

16. Lim CC. Anthracyclines induce calpain-dependent titin prolyl hydroxylation and necrosis in cardiomyocytes. J Biol Chem. 2004;279:8290–8299.

17. Montaigne D, Marechal X, Preau S, et al. Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion. 2011;11:22–26.

18. Von Hoff DD, Layard MW, Basa P. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717.

19. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–1084.

20. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2005;97:2869–2879.

21. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–1988.

22. Lotsonite M, Blondi-Zoccai G, Abbate A, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112:1980–1984.

23. Mancini D, Edvardsen T, Mørk E, et al. Decrease in doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133–139.

24. Waterhouse DN, Tardi PG, Mayer LD. A comparison of liposomal formulations of doxorubicin with doxorubicin in free form changing toxicity profiles. Drug Saf. 2001;24:903–920.

26. U.S. Food and Drug Administration. FDA statement on doxorubicin. http://www.fda.gov/drugsafety/ucm26729.htm. Published July, 2010. Accessed October 24, 2011.

27. Ammar el SM, Said SA, Suddek GM, et al. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats. Can J Physiol Pharmocol. 2011;89:269–276.

28. Lipshultz SE, Riai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145–153.

29. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950–961.

30. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1984;74:1124–1136.

31. Frohlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J. 2013;34:1714–1722.

32. Lipshultz SE, Karnik R, Sambatakos P, et al. Anthracycline-related cardiotoxicity in childhood cancer survivors. Curr Opin Cardiol. 2014;29:103–112.

33. Lebrecht D, Walker UA. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:108–113.

34. Jirkovsky E, Popovola O, Krvivkova-Stankova P, et al. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways. J Pharmacol Exp Ther. 2012;343:468–478.

35. Gharani M, Hussain A, Janneh O, et al. Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore. Toxicol Appl Pharmacol. 2013;268:149–156.

36. Sandhu H, Maddock H. Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clin Sci (Lond). 2014;126:377–400.

37. Sterba M, Popovola O, Vávrova A, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal. 2013;18:899–929.

38. Cancer Research UK. Cancer statistics for the UK. Cancer mortality 2012. http://www.cancerresearchuk.org/health-professional/cancer-statistics. Accessed October 27, 2014.

39. Kubo T, Kitaoka H, Yamanaka S, et al. Significance of high-sensitivity cardiac troponin T in hypertrrophic cardiomyopathy. J Am Coll Cardiol. 2013;62:1252–1259.

40. Palladini G, Barassi M, Mari A, et al. The combination of high-sensitivity cardiac troponin T (hs-TnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116:3426–3430.

41. Feustel A, Hahn A, Schneider C, et al. Continuous cardiac troponin I release in Fabry disease. PLoS One. 2014;9:e91757.

42. Zografos TA, Katrissis GD, Tsifoutis I, et al. Effect of one-cycle remote ischemic preconditioning to reduce myocardial injury during percutaneous coronary intervention. Am J Cardiol. 2014;113:2013–2017.

43. Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiotoxic risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:3159–3165.

44. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381.

45. Candillo L, Malik A, Ariti C, et al. Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial. Heart. 2015;101:185–192.
46. Hidalgo JD, Krone R, Rich MW, et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2004;34:615–619.

47. Hu YF, Liu CJ, Chang PM, et al. Incident thromboembolism and heart failure association with new-onset atrial fibrillation in cancer patients. Int J Cardiol. 2013;165:355–357.

48. Kilickap S, Barista I, Akgul E, et al. Early and late arrhythmogenic effects of doxorubicin. South Med J. 2007;100:262–265.

49. Okuma K, Furuta I, Ota K. Acute cardiotoxicity of anthracyclines—analysis by using Holter ECG [in Japanese]. Gan To Kagaku Ryoho. 1984;11:902–911.

50. Cove-Smith L, Woodhouse N, Hargreaves A, et al. An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. Toxicol Sci. 2014;140:3–15.

51. Montaigne D, Marechal X, Lefevbre P, et al. Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome in whom post-operative atrial fibrillation develops. J Am Coll Cardiol. 2013;62:1466–1473.

52. Dresdale AR, Barr LH, Bono RO. Prospective randomized study of the role of N-acetylcysteine in reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol. 1982;5:657–663.

53. Wu X. The oral iron chelator IC 760A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med. 2003;35:1449–1479.

54. van Dalen EC, Raphael MF, Caron HN, et al. Treatment including anthracyclines versus treatment not including anthracyclines for childhood Cancer. Cochrane Database Syst Rev. 2014;8:CD006647.

55. Funahashi K, Onishi K, Dohi K, et al. Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. Am J Physiol Heart Circ Physiol. 2004;287:H2487–H2492.

56. Seicean S, Seicean A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60:2384–2390.

57. Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167:2306–2310.

58. Seicean S, Seicean A, Alan N, et al. Cardioprotective effect of Beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6:420–428.

59. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardio toxicity in high-risk patients by angiotensin-converting enzyme inhibition. Ann Oncol. 2003;14:215–220.

60. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Heart Fail. 2013;15:2900–2909.

61. Hellmann K. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: a claim without evidence. J Clin Oncol. 2007;25:4689–4690.

62. Lipszultz SE, Lipsitz SR, Orav EJ. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: a claim without compelling evidence. J Clin Oncol. 2007;25:3179–3180.

63. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk of acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25:493–500.

64. R. Chung et al: The ERIC-ONC study

65. Clin Cardiol. 39, 2, 72–82 (2016)

66. Hidalgo JD, Krone R, Rich MW, et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2004;34:615–619.

67. Hu YF, Liu CJ, Chang PM, et al. Incident thromboembolism and heart failure association with new-onset atrial fibrillation in cancer patients. Int J Cardiol. 2013;165:355–357.

68. Kilickap S, Barista I, Akgul E, et al. Early and late arrhythmogenic effects of doxorubicin. South Med J. 2007;100:262–265.

69. Okuma K, Furuta I, Ota K. Acute cardiotoxicity of anthracyclines—analysis by using Holter ECG [in Japanese]. Gan To Kagaku Ryoho. 1984;11:902–911.

70. Cove-Smith L, Woodhouse N, Hargreaves A, et al. An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. Toxicol Sci. 2014;140:3–15.
88. Rentoukas I, Giannopoulos G, Kaoukis A, et al. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv. 2010;3:49–55.

89. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischemic conditioning before hospital admission, as a complement to angioplasty and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727–734.

90. White SK, Frohlich GM, Sado DM, et al. Remote Ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2014;14:01073–01075.

91. Bautin AE, Galagudza MM, Datsenko SV, et al. Effects of remote ischemic preconditioning on perioperative period in elective aortic valve replacement [in Russian]. Anesteziol Reanimatol. 2014;(3):11–17.

92. Zarbock A, Schmidt C, Van Alen H, et al. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA. 2015;313:2133–2141.

93. Sloth AD, Schmidt MR, Munk K, et al. CONDI Investigators. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J. 2014;35:168–175.

94. Hausenloy DJ, Candiolo L, Laing C, et al. Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clin Res Cardiol. 2012;101:330–348.

95. Maxwell YL. ERICCA: remote ischemic preconditioning fails to improve long-term outcomes after CABG. TCTMD website. http://www.tctmd.com/txshow.aspx?id=128251&trid=2. Published March 16, 2015. Accessed March 16, 2015.

96. Martin-Gill C, Wayne M, Guyette FX, et al. Feasibility of remote ischemic per-conditioning during air medical transport of STEMI patients [published online August 13, 2015]. Prehosp Emerg Care. doi:10.3109/10903127.2015.106684.

97. Li C, Xu M, Wu Y, et al. Limb remote ischemic preconditioning attenuates lung injury after pulmonary resection under propofol-remifentanil anesthesia: a randomized controlled study. Anesthesiology. 2014;121:249–259.

98. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517–522.

99. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003;49:248–252.

100. Haney S, Cresti N, Verrill M, et al. Cardiac troponin release following standard dose anthracycline-based adjuvant chemotherapy [abstract]. Eur Heart J. 2013;34(suppl 1):1074.